GLP-1 lawsuits and gastroparesis: what the evidence and the litigation actually show

"GLP-1 lawsuit" is now a common enough search that it's worth addressing directly and plainly — separating the actual clinical evidence about gastrointestinal side effects from the separate, ongoing question of where the litigation stands and what it does and doesn't prove.

The clinical evidence behind the concern

Delayed gastric emptying is a known, labeled mechanism of how GLP-1s work — it's part of why they reduce appetite. Gastroparesis, a more severe and less common condition where the stomach empties too slowly on a sustained basis, is a distinct clinical diagnosis from ordinary GLP-1 nausea. A study published in JAMA compared new GLP-1 users against users of another weight-loss drug class and found a higher relative rate of several gastrointestinal diagnoses — including gastroparesis, along with pancreatitis and bowel obstruction — though the authors were clear that these remain rare events in absolute terms, and the study's design (comparing prescription claims data) can identify an association without proving that the drug caused every case¹. That distinction — a real, published, higher relative rate of a rare event versus proof of individual causation — is exactly the kind of nuance that gets lost in both marketing and legal advertising.

Where the federal litigation stands

The lawsuits themselves have been consolidated into a single federal proceeding: MDL No. 3094, formally "In re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation," centralized in the U.S. District Court for the Eastern District of Pennsylvania before Judge Karen S. Marston. The cases allege that Novo Nordisk (Ozempic, Wegovy, Rybelsus) and Eli Lilly (Trulicity, Mounjaro) knew or should have known about a risk of gastroparesis and other gastrointestinal injuries and didn't adequately warn patients and prescribers². Both manufacturers deny the allegations. As of this writing, the litigation is in active pretrial proceedings, with the court holding monthly status conferences — it has not been resolved, and no liability has been established or admitted by either manufacturer. That status can change; if you're tracking it for a personal decision, the court's own docket is the most reliable source of where things actually stand today, not a law firm's marketing page.

What this doesn't mean for your own decision

An active lawsuit alleging inadequate warning is not the same as proof the drug caused a specific plaintiff's condition, and it's not evidence that gastroparesis is a common outcome — the JAMA study itself frames it as a rare event among a much larger group of people who don't experience it. If you're currently on a GLP-1 and experiencing normal early-titration nausea that settles between dose increases, that's expected and different from persistent, worsening symptoms; our GLP-1 side effects: what to expect guide covers where that line typically falls. Severe, persistent abdominal pain, an inability to keep food or fluids down for more than a day, or symptoms that get worse rather than settle after a dose increase are the signals worth calling your prescriber about promptly, regardless of what the litigation eventually concludes.

Why this belongs in provider vetting, not just legal news

One practical takeaway that isn't about the lawsuits at all: a provider running a real clinical intake should be asking about your GI history and monitoring you through titration, not just shipping a pen after a five-minute form. See how to choose a GLP-1 provider for what that screening should actually include — it's the same due diligence that matters regardless of how the MDL resolves.

The honest bottom line

The underlying clinical signal is real and published, the absolute risk is described as rare, and the litigation is genuinely ongoing and unresolved — not settled, not dismissed, not proof of anything about any specific case yet. Reporting all three of those facts together is more useful than either dismissing the concern or treating an active lawsuit as a verdict. This is a summary of publicly available clinical research and court records, not legal or medical advice; a doctor is the right resource for your symptoms, and an attorney is the right resource for a legal claim.